SCH-C

Drug Description

SCH-C is an oxime-piperidine compound. [1]

HIV/AIDS-Related Uses

SCH-C is a CCR5 receptor antagonist being investigated for the treatment of HIV. SCH-C has been studied in Phase 1 clinical trials in healthy volunteers and in HIV infected patients.[2] Currently, SCH-D, another CCR5 receptor antagonist being developed by Schering-Plough, has been assigned priority status over SCH-C due to SCH-D's increased antiviral potency.[3]

Pharmacology

CCR5 is the coreceptor used by the most commonly transmitted macrophage-tropic HIV-1 strains, which predominate during the early stages of HIV infection.[4] SCH-C binds to the transmembrane domain of CCR5. This is thought to disrupt the conformation of CCR5's extracellular domain, thereby inhibiting ligand binding to CCR5.[5]

In a Phase I clinical trial in HIV infected adults, the mean Cmax and Cmin levels of SCH-C at steady state were approximately 140 nM and 90 nM, respectively. There was a short lag time (2 to 3 days) in effect and a prolonged effect following cessation of dosing. Ten of twelve patients had at least a 0.5 log10 reduction in viral load from baseline.[6]

Adverse Events/Toxicity

SCH-C has been shown generally safe and well tolerated in both healthy volunteers and HIV infected adults. Mild headache and bad taste in the mouth were both reported.

One case of an isolated triplet on EKG was reported. Prolongation of the QTc interval was noted at higher doses among healthy volunteers.[7] [8]

Drug and Food Interactions

SCH-C is synergistic in vitro with zidovudine, lamivudine, efavirenz, indinavir, and enfuvirtide.[9]

Clinical Trials

For information on clinical trials that involve SCH-C, visit the ClinicalTrials.gov web site at http://www.clinicaltrials.gov. In the Search box, enter: SCH-C AND HIV Infections.

Dosing Information

Mode of Delivery: Oral.[10]

Other Names

SCH 351125[11]

SCH-351125[12]

Further Reading

Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol. 2003 May;77(9):5201-8.

Ketas TJ, Klasse PJ, Spenlehauer C, Nesin M, Frank I, Pope M, Strizki JM, Reyes GR, Baroudy BM, Moore JP. Entry inhibitors SCH-C, RANTES, and T-20 block HIV type 1 replication in multiple cell types. AIDS Res Hum Retroviruses. 2003 Mar;19(3):177-86.

Este JA. Sch-351125 and Sch-350634. Schering-Plough. Curr Opin Investig Drugs. 2002 Mar;3(3):379-83.

Tremblay CL, Giguel F, Kollmann C, Guan Y, Chou TC, Baroudy BM, Hirsch MS. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob Agents

Further Reading (cont.)

Chemother. 2002 May;46(5):1336-9.

Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):395-400.

Manufacturer Information

SCH-C
Schering - Plough Corp
2000 Galloping Hill Rd
Kenilworth, NJ 07033-0530
(800) 526-4099

For More Information

Contact your doctor or an AIDSinfo Health Information Specialist:

• Via Phone: 1-800-448-0440 Monday - Friday, 12:00 p.m. (Noon) - 5:00 p.m. ET

• Via Live Help: http://aidsinfo.nih.gov/live_help Monday - Friday, 12:00 p.m. (Noon) - 4:00 p.m. ET

References

1. Proc Natl Acad Sci USA - 2001 October;98(22):12718-23.

2. Conf Retroviruses Opportunistic Infect. - 9th. 2002. Abstract 1.

3. Communication - Personal, with Aracelia Villa. 10/30/03.

4. Proc Natl Acad Sci USA - 2001 October;98(22):12718-23.

5. J Virol - 2003 May;77(9):5201-8.

6. Conf Retroviruses Opportunistic Infect. - 9th. 2002. Abstract 1.

7. Conf Retroviruses Opportunistic Infect. - 9th. 2002. Abstract 1.

8. Schering Plough - Schering Plough. Available at http://www.sch-plough.com/. Accessed 10/290/03.

9. Antimicrob Agents Chemother - 2002 May;46(5):1336-9.

10. Conf Retroviruses Opportunistic Infect. - 9th. 2002. Abstract 1.

11. Antimicrob Agents Chemother - 2002 May;46(5):1336-9.

12. J Virol - 2003 May;77(9):5201-8.